These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

605 related items for PubMed ID: 28397992

  • 1. Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis.
    Tarrant BJ, Le Maitre C, Romero L, Steward R, Button BM, Thompson BR, Holland AE.
    Respirology; 2017 Aug; 22(6):1084-1092. PubMed ID: 28397992
    [Abstract] [Full Text] [Related]

  • 2. Pharmacologic agents for mucus clearance in bronchiectasis.
    Nair GB, Ilowite JS.
    Clin Chest Med; 2012 Jun; 33(2):363-70. PubMed ID: 22640851
    [Abstract] [Full Text] [Related]

  • 3. Pharmacotherapy of impaired mucociliary clearance in non-CF pediatric lung disease. A review of the literature.
    Boogaard R, de Jongste JC, Merkus PJ.
    Pediatr Pulmonol; 2007 Nov; 42(11):989-1001. PubMed ID: 17902149
    [Abstract] [Full Text] [Related]

  • 4. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
    King M, Dasgupta B, Tomkiewicz RP, Brown NE.
    Am J Respir Crit Care Med; 1997 Jul; 156(1):173-7. PubMed ID: 9230743
    [Abstract] [Full Text] [Related]

  • 5. Nebulised hypertonic saline for cystic fibrosis.
    Wark P, McDonald VM.
    Cochrane Database Syst Rev; 2018 Sep 27; 9(9):CD001506. PubMed ID: 30260472
    [Abstract] [Full Text] [Related]

  • 6. Dornase alfa for cystic fibrosis.
    Yang C, Montgomery M.
    Cochrane Database Syst Rev; 2021 Mar 18; 3(3):CD001127. PubMed ID: 33735508
    [Abstract] [Full Text] [Related]

  • 7. Dornase alfa for cystic fibrosis.
    Yang C, Montgomery M.
    Cochrane Database Syst Rev; 2018 Sep 06; 9(9):CD001127. PubMed ID: 30187450
    [Abstract] [Full Text] [Related]

  • 8. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.
    Bilton D, Tino G, Barker AF, Chambers DC, De Soyza A, Dupont LJ, O'Dochartaigh C, van Haren EH, Vidal LO, Welte T, Fox HG, Wu J, Charlton B, B-305 Study Investigators.
    Thorax; 2014 Dec 06; 69(12):1073-9. PubMed ID: 25246664
    [Abstract] [Full Text] [Related]

  • 9. The expanding armamentarium of drugs to aid sputum clearance: how should they be used to optimize care?
    Bilton D, Stanford G.
    Curr Opin Pulm Med; 2014 Nov 06; 20(6):601-6. PubMed ID: 25221855
    [Abstract] [Full Text] [Related]

  • 10. Dornase alfa for cystic fibrosis.
    Yang C, Chilvers M, Montgomery M, Nolan SJ.
    Cochrane Database Syst Rev; 2016 Apr 04; 4():CD001127. PubMed ID: 27043279
    [Abstract] [Full Text] [Related]

  • 11. Inhaled mannitol for cystic fibrosis.
    Nevitt SJ, Thornton J, Murray CS, Dwyer T.
    Cochrane Database Syst Rev; 2020 May 01; 5(5):CD008649. PubMed ID: 32358807
    [Abstract] [Full Text] [Related]

  • 12. Mucoactive agents for adults with acute lung conditions: A systematic review.
    Tarrant BJ, Maitre CL, Romero L, Steward R, Button BM, Thompson BR, Holland AE.
    Heart Lung; 2019 May 01; 48(2):141-147. PubMed ID: 30409442
    [Abstract] [Full Text] [Related]

  • 13. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis.
    Laube BL, Auci RM, Shields DE, Christiansen DH, Lucas MK, Fuchs HJ, Rosenstein BJ.
    Am J Respir Crit Care Med; 1996 Feb 01; 153(2):752-60. PubMed ID: 8564129
    [Abstract] [Full Text] [Related]

  • 14. Inhaled mannitol for cystic fibrosis.
    Nevitt SJ, Thornton J, Murray CS, Dwyer T.
    Cochrane Database Syst Rev; 2018 Feb 09; 2(2):CD008649. PubMed ID: 29424930
    [Abstract] [Full Text] [Related]

  • 15. Inhaled mucoactive drugs for treating non-cystic fibrosis bronchiectasis in children.
    Snijders D, Calgaro S, Bertozzi I, Quartesan S, Kozuh I, Lunardi F, Barbato A.
    Int J Immunopathol Pharmacol; 2013 Feb 09; 26(2):529-34. PubMed ID: 23755770
    [Abstract] [Full Text] [Related]

  • 16. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis.
    Kellett F, Robert NM.
    Respir Med; 2011 Dec 09; 105(12):1831-5. PubMed ID: 22018993
    [Abstract] [Full Text] [Related]

  • 17. The use of pulmonary clearance medications in the acutely ill patient.
    Papacostas MF, Luckett P, Hupp S.
    Expert Rev Respir Med; 2017 Oct 09; 11(10):815-826. PubMed ID: 28780895
    [Abstract] [Full Text] [Related]

  • 18. Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial.
    Herrero-Cortina B, Alcaraz V, Vilaró J, Torres A, Polverino E.
    J Aerosol Med Pulm Drug Deliv; 2018 Oct 09; 31(5):281-289. PubMed ID: 29878856
    [Abstract] [Full Text] [Related]

  • 19. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability.
    Wills PJ, Wodehouse T, Corkery K, Mallon K, Wilson R, Cole PJ.
    Am J Respir Crit Care Med; 1996 Aug 09; 154(2 Pt 1):413-7. PubMed ID: 8756815
    [Abstract] [Full Text] [Related]

  • 20. Rational use of mucoactive medications to treat pediatric airway disease.
    Linssen RSN, Ma J, Bem RA, Rubin BK.
    Paediatr Respir Rev; 2020 Nov 09; 36():8-14. PubMed ID: 32653467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.